What is the projected market valuation of the Kidney Transplantation Therapeutics Market by 2035?

The projected market valuation for the Kidney Transplantation Therapeutics Market is 22.02 USD Billion by 2035. Read More

What was the market valuation of the Kidney Transplantation Therapeutics Market in 2024?

The overall market valuation was 12.08 USD Billion in 2024. Read More

What is the expected CAGR for the Kidney Transplantation Therapeutics Market during the forecast period 2025 - 2035?

The expected CAGR for the Kidney Transplantation Therapeutics Market during the forecast period 2025 - 2035 is 5.61%. Read More

Which companies are considered key players in the Kidney Transplantation Therapeutics Market?

Key players in the market include Astellas Pharma, Novartis, Roche, Bristol-Myers Squibb, Pfizer, AbbVie, Sanofi, Merck & Co., and Teva Pharmaceutical Industries. Read More

What are the market segments for the Kidney Transplantation Therapeutics Market?

The market segments include Type of Transplantation, Immunosuppressant Drugs, Biologics, Surgical Approach, and End-User. Read More

What is the valuation range for Living Donor Kidney Transplantation in 2025?

The valuation for Living Donor Kidney Transplantation is projected to range from 6.04 to 11.0 USD Billion in 2025. Read More

How does the market for Immunosuppressant Drugs appear in terms of valuation?

The Immunosuppressant Drugs segment is expected to have a valuation ranging from 3.0 to 6.0 USD Billion for Mycophenolate Mofetil in 2025. Read More

What is the projected valuation for Robot-Assisted Surgery in 2025?

The projected valuation for Robot-Assisted Surgery is anticipated to range from 3.64 to 6.62 USD Billion in 2025. Read More

What is the expected valuation for hospitals as an end-user in the Kidney Transplantation Therapeutics Market?

The expected valuation for hospitals as an end-user is projected to range from 4.82 to 8.8 USD Billion in 2025. Read More

What does the market data suggest about the future of Deceased Donor Kidney Transplantation?

The market data suggests that Deceased Donor Kidney Transplantation will have a valuation range of 6.04 to 11.02 USD Billion in 2025. Read More

Kidney Transplantation Therapeutics Market

Kidney Transplantation Therapeutics Market Research Report By Type of Transplantation (Living Donor Kidney Transplantation, Deceased Donor Kidney Transplantation), By Immunosuppressant Drugs (Tacrolimus, Cyclosporine, Azathioprine, Mycophenolate Mofetil, Sirolimus), By Biologics (Eculizumab, Belimumab, Rituximab), By Surgical Approach (Open Surgery, Laparoscopic Surgery, Robot-Assisted Surgery), By End-User (Hospitals, Transplant Centers, Ambulatory Surgery Centers, Outpatient Clinics) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) – Industry Forecast to 2035

Forecast Period

2025 - 2035

CAGR

5.61%

2024 Market Size

$ 12.08 Billion

2035 Market Size

$ 22.02 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/38790-HCR | Pages: 128 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Transplantation (USD Billion) | |
  1. 4.1.1 Living Donor Kidney Transplantation | |
  2. 4.1.2 Deceased Donor Kidney Transplantation |
2. 4.2 Healthcare, BY Immunosuppressant Drugs (USD Billion) | |
  1. 4.2.1 Tacrolimus | |
  2. 4.2.2 Cyclosporine | |
  3. 4.2.3 Azathioprine | |
  4. 4.2.4 Mycophenolate Mofetil | |
  5. 4.2.5 Sirolimus |
3. 4.3 Healthcare, BY Biologics (USD Billion) | |
  1. 4.3.1 Eculizumab | |
  2. 4.3.2 Belimumab | |
  3. 4.3.3 Rituximab |
4. 4.4 Healthcare, BY Surgical Approach (USD Billion) | |
  1. 4.4.1 Open Surgery | |
  2. 4.4.2 Laparoscopic Surgery | |
  3. 4.4.3 Robot-Assisted Surgery |
5. 4.5 Healthcare, BY End-User (USD Billion) | |
  1. 4.5.1 Hospitals | |
  2. 4.5.2 Transplant Centers | |
  3. 4.5.3 Ambulatory Surgery Centers | |
  4. 4.5.4 Outpatient Clinics |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Astellas Pharma (JP) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novartis (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Roche (CH) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Bristol-Myers Squibb (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Pfizer (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 AbbVie (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Merck & Co. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Teva Pharmaceutical Industries (IL) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
7. 6.4 US MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
8. 6.5 US MARKET ANALYSIS BY BIOLOGICS |
9. 6.6 US MARKET ANALYSIS BY SURGICAL APPROACH |
10. 6.7 US MARKET ANALYSIS BY END-USER |
11. 6.8 CANADA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
12. 6.9 CANADA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
13. 6.10 CANADA MARKET ANALYSIS BY BIOLOGICS |
14. 6.11 CANADA MARKET ANALYSIS BY SURGICAL APPROACH |
15. 6.12 CANADA MARKET ANALYSIS BY END-USER |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
18. 6.15 GERMANY MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
19. 6.16 GERMANY MARKET ANALYSIS BY BIOLOGICS |
20. 6.17 GERMANY MARKET ANALYSIS BY SURGICAL APPROACH |
21. 6.18 GERMANY MARKET ANALYSIS BY END-USER |
22. 6.19 UK MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
23. 6.20 UK MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
24. 6.21 UK MARKET ANALYSIS BY BIOLOGICS |
25. 6.22 UK MARKET ANALYSIS BY SURGICAL APPROACH |
26. 6.23 UK MARKET ANALYSIS BY END-USER |
27. 6.24 FRANCE MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
28. 6.25 FRANCE MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
29. 6.26 FRANCE MARKET ANALYSIS BY BIOLOGICS |
30. 6.27 FRANCE MARKET ANALYSIS BY SURGICAL APPROACH |
31. 6.28 FRANCE MARKET ANALYSIS BY END-USER |
32. 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
33. 6.30 RUSSIA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
34. 6.31 RUSSIA MARKET ANALYSIS BY BIOLOGICS |
35. 6.32 RUSSIA MARKET ANALYSIS BY SURGICAL APPROACH |
36. 6.33 RUSSIA MARKET ANALYSIS BY END-USER |
37. 6.34 ITALY MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
38. 6.35 ITALY MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
39. 6.36 ITALY MARKET ANALYSIS BY BIOLOGICS |
40. 6.37 ITALY MARKET ANALYSIS BY SURGICAL APPROACH |
41. 6.38 ITALY MARKET ANALYSIS BY END-USER |
42. 6.39 SPAIN MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
43. 6.40 SPAIN MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
44. 6.41 SPAIN MARKET ANALYSIS BY BIOLOGICS |
45. 6.42 SPAIN MARKET ANALYSIS BY SURGICAL APPROACH |
46. 6.43 SPAIN MARKET ANALYSIS BY END-USER |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY BIOLOGICS |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY SURGICAL APPROACH |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY END-USER |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
54. 6.51 CHINA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
55. 6.52 CHINA MARKET ANALYSIS BY BIOLOGICS |
56. 6.53 CHINA MARKET ANALYSIS BY SURGICAL APPROACH |
57. 6.54 CHINA MARKET ANALYSIS BY END-USER |
58. 6.55 INDIA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
59. 6.56 INDIA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
60. 6.57 INDIA MARKET ANALYSIS BY BIOLOGICS |
61. 6.58 INDIA MARKET ANALYSIS BY SURGICAL APPROACH |
62. 6.59 INDIA MARKET ANALYSIS BY END-USER |
63. 6.60 JAPAN MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
64. 6.61 JAPAN MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
65. 6.62 JAPAN MARKET ANALYSIS BY BIOLOGICS |
66. 6.63 JAPAN MARKET ANALYSIS BY SURGICAL APPROACH |
67. 6.64 JAPAN MARKET ANALYSIS BY END-USER |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY BIOLOGICS |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY SURGICAL APPROACH |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY END-USER |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
74. 6.71 MALAYSIA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
75. 6.72 MALAYSIA MARKET ANALYSIS BY BIOLOGICS |
76. 6.73 MALAYSIA MARKET ANALYSIS BY SURGICAL APPROACH |
77. 6.74 MALAYSIA MARKET ANALYSIS BY END-USER |
78. 6.75 THAILAND MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
79. 6.76 THAILAND MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
80. 6.77 THAILAND MARKET ANALYSIS BY BIOLOGICS |
81. 6.78 THAILAND MARKET ANALYSIS BY SURGICAL APPROACH |
82. 6.79 THAILAND MARKET ANALYSIS BY END-USER |
83. 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
84. 6.81 INDONESIA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
85. 6.82 INDONESIA MARKET ANALYSIS BY BIOLOGICS |
86. 6.83 INDONESIA MARKET ANALYSIS BY SURGICAL APPROACH |
87. 6.84 INDONESIA MARKET ANALYSIS BY END-USER |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
89. 6.86 REST OF APAC MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
90. 6.87 REST OF APAC MARKET ANALYSIS BY BIOLOGICS |
91. 6.88 REST OF APAC MARKET ANALYSIS BY SURGICAL APPROACH |
92. 6.89 REST OF APAC MARKET ANALYSIS BY END-USER |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
95. 6.92 BRAZIL MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
96. 6.93 BRAZIL MARKET ANALYSIS BY BIOLOGICS |
97. 6.94 BRAZIL MARKET ANALYSIS BY SURGICAL APPROACH |
98. 6.95 BRAZIL MARKET ANALYSIS BY END-USER |
99. 6.96 MEXICO MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
100. 6.97 MEXICO MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
101. 6.98 MEXICO MARKET ANALYSIS BY BIOLOGICS |
102. 6.99 MEXICO MARKET ANALYSIS BY SURGICAL APPROACH |
103. 6.100 MEXICO MARKET ANALYSIS BY END-USER |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
105. 6.102 ARGENTINA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
106. 6.103 ARGENTINA MARKET ANALYSIS BY BIOLOGICS |
107. 6.104 ARGENTINA MARKET ANALYSIS BY SURGICAL APPROACH |
108. 6.105 ARGENTINA MARKET ANALYSIS BY END-USER |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOLOGICS |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY SURGICAL APPROACH |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY BIOLOGICS |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY SURGICAL APPROACH |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY BIOLOGICS |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY SURGICAL APPROACH |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF TRANSPLANTATION |
126. 6.123 REST OF MEA MARKET ANALYSIS BY IMMUNOSUPPRESSANT DRUGS |
127. 6.124 REST OF MEA MARKET ANALYSIS BY BIOLOGICS |
128. 6.125 REST OF MEA MARKET ANALYSIS BY SURGICAL APPROACH |
129. 6.126 REST OF MEA MARKET ANALYSIS BY END-USER |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TYPE OF TRANSPLANTATION, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TYPE OF TRANSPLANTATION, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY IMMUNOSUPPRESSANT DRUGS, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY IMMUNOSUPPRESSANT DRUGS, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY BIOLOGICS, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY BIOLOGICS, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY SURGICAL APPROACH, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY SURGICAL APPROACH, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY END-USER, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY END-USER, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY END-USER, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY END-USER, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY END-USER, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY END-USER, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY END-USER, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY END-USER, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY END-USER, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY END-USER, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY END-USER, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY END-USER, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY END-USER, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY END-USER, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY END-USER, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY END-USER, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY END-USER, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY END-USER, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY END-USER, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY END-USER, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY END-USER, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY END-USER, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY END-USER, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY END-USER, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY END-USER, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY END-USER, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY END-USER, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY END-USER, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF TRANSPLANTATION, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY IMMUNOSUPPRESSANT DRUGS, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY BIOLOGICS, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY SURGICAL APPROACH, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY END-USER, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Kidney Transplantation Therapeutics Market Segmentation

Kidney Transplantation Therapeutics Market By Type of Transplantation (USD Billion, 2025-2035)

Living Donor Kidney Transplantation
Deceased Donor Kidney Transplantation

Kidney Transplantation Therapeutics Market By Immunosuppressant Drugs (USD Billion, 2025-2035)

Tacrolimus
Cyclosporine
Azathioprine
Mycophenolate Mofetil
Sirolimus

Kidney Transplantation Therapeutics Market By Biologics (USD Billion, 2025-2035)

Eculizumab
Belimumab
Rituximab

Kidney Transplantation Therapeutics Market By Surgical Approach (USD Billion, 2025-2035)

Open Surgery
Laparoscopic Surgery
Robot-Assisted Surgery

Kidney Transplantation Therapeutics Market By End-User (USD Billion, 2025-2035)

Hospitals
Transplant Centers
Ambulatory Surgery Centers
Outpatient Clinics

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035